Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-α/β and CD19 Depleted HSCT in Relapsed Lymphoma
NCT02652468Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2016
- Primary completion
- Sep 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of TCR alpha-beta/CD19-depleted hematopoietic stem cells in lymphoma, sponsored by University of Wisconsin–Madison. Started Mar 2016; status: completed.
02
Drugs
TCR alpha-beta/CD19-depleted hematopoietic stem cells
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT02652468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652468.